Lymphoma, B-Cell: all 1,415 studies
Page 14 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell LymphomaCompletedNCT00761384Phase 1/2
- Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)CompletedNCT00754117
- A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT00741871Phase 1
- Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00717925Phase 1
- Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell LymphomaCompletedNCT00689169Phase 2
- Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaCompletedNCT00644124Phase 1
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
- Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00612183Phase 2
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00599170Phase 2
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLActive, not recruitingNCT00586391Phase 1
- Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell LymphomaCompletedNCT00575406Phase 2
- Vaccine Therapy in Treating Patients With Recurrent B-Cell LymphomaCompletedNCT00561756Phase 1
- Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-RituximabCompletedNCT00561379Not applicable
- R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell LymphomasCompletedNCT00558220Phase 2
- A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedNCT00556699Phase 1
- Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell LymphomaCompletedNCT00556127Phase 2
- Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at DiagnosisCompletedNCT00553943Phase 2
- Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's LymphomaCompletedNCT00549185Phase 1
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
- A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaWithdrawnNCT00538096Phase 1
- FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell LymphomaCompletedNCT00530179Not applicable
- Study Evaluating TRU-015 in B-Cell Non-Hodgkin's LymphomaTerminatedNCT00521638Phase 1
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell LymphomaStatus unknownNCT00499018Phase 3
- Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) SubjectsTerminatedNCT00498914Phase 2
- A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in LymphomaCompletedNCT00498043Phase 2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical TrialsCompletedNCT00487513
- LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)CompletedNCT00466258Phase 4
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT00455897Phase 2
- The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOPCompletedNCT00440583Phase 2
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantCompletedNCT00434629Phase 1
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
- Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9Status unknownNCT00400907
- A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13CompletedNCT00400478Phase 3
- Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaStatus unknownNCT00397800Phase 1/2
- Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell LymphomaCompletedNCT00394693Phase 2
- Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell LymphomaTerminatedNCT00386321Phase 2
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell LymphomaCompletedNCT00338494Phase 1
- Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's LymphomaCompletedNCT00336843Phase 2
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.Status unknownNCT00333008Phase 2
- Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid TreatmentStatus unknownNCT00324467Phase 2
- Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell LymphomaCompletedNCT00316511Phase 1
- Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
- Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IVCompletedNCT00286832
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's LymphomaCompletedNCT00271050Phase 1
- Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CTCompletedNCT00256490Not applicable
- Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00220285Phase 2
- Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaTerminatedNCT00216164Phase 2
- A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's LymphomaCompletedNCT00211276Phase 2
- Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's LymphomaCompletedNCT00210379Phase 2
- Salvage Therapy With Idarubicin in Relapsing CNS LymphomaTerminatedNCT00210366Phase 2
- A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous MeningitisWithdrawnNCT00210340Phase 1
- Phase II Trial of Combined Modality Treatment in Primary Central Nervous System LymphomaCompletedNCT00210314Phase 2
- Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's DiseaseTerminatedNCT00209014Phase 2
- Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00204659Phase 2
- Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALTomaCompletedNCT00201422Not applicable
- Association of Velcade to R-CHOP in the Treatment of B Cell LymphomaCompletedNCT00169468Phase 2
- Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell LymphomaCompletedNCT00169195Phase 2
- Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell LymphomaTerminatedNCT00169169Phase 3
- Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell LymphomaCompletedNCT00169143Phase 2
- Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)CompletedNCT00168740Phase 3
- Treatment of Mature B-cell Lymphoma/LeukaemiaCompletedNCT00162656Phase 3
- Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)CompletedNCT00147121Phase 2/3
- Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell LymphomaCompletedNCT00138086Phase 2
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
- An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)CompletedNCT00097929Phase 2
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
- Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
- VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
- Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00062296Phase 2
- Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGCompletedNCT00061425Phase 1/2
- Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
- Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
- Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesCompletedNCT00051597Phase 1/2
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
- Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With ChemotherapyCompletedNCT00038571Phase 2
- Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1